Obesity Drug Market Set to Boom: Two Challengers Could Double as $100B Market Beckons

The global obesity treatment market is experiencing unprecedented momentum, with projections pointing toward a staggering $100 billion market by decade's end. While Eli Lilly ($LLY) and Novo Nordisk ($NVO) have long dominated this space with blockbuster GLP-1 receptor agonists like tirzepatide and semaglutide, two emerging competitors—Viking Therapeutics and AbbVie ($ABBV)—are positioning themselves for potentially transformative growth as they advance novel compounds through critical development stages. Industry analysts and investors are increasingly bullish on these challengers, with some predicting their stock valuations could double by 2026 as late-stage trial results materialize and market demand for obesity treatments continues its explosive trajectory.

The Next Wave of Innovation in Obesity Treatment

The obesity pharmaceutical landscape is shifting beyond the current GLP-1 dominance as companies explore next-generation mechanisms of action. Viking Therapeutics is at the forefront with VK-2735, a dual GLP-1/GIP receptor agonist candidate currently advancing through phase 3 clinical trials. The compound's mechanism is noteworthy: by targeting both GLP-1 and GIP receptors simultaneously, VK-2735 aims to deliver superior efficacy compared to existing single-target therapies currently available on the market.

Initial trial results for VK-2735 have proven promising, generating considerable enthusiasm among investors and clinicians alike. The phase 3 data trajectory will be critical in determining whether Viking can establish meaningful market differentiation. Success in these trials would position the company to capture significant share from the expanding obesity treatment market as patients and physicians seek alternatives with potentially improved efficacy or safety profiles.

AbbVie is pursuing a different mechanistic approach with ABBV-295, a long-acting amylin analog. While GLP-1 agonists have dominated recent headlines, amylin-based therapeutics represent a distinct pharmacological pathway with its own clinical rationale. Early-stage phase 1 data for ABBV-295 has been positive, suggesting the compound warrants continued development. The long-acting formulation design addresses a key patient consideration—dosing frequency and convenience—which could become a significant competitive advantage as the obesity drug market matures.

Market Context: A Massive Opportunity With Growing Competition

The obesity treatment market stands at an inflection point. Current market penetration remains low despite enormous disease prevalence, suggesting substantial room for expansion. The global obesity epidemic continues accelerating, with rising prevalence rates across developed and emerging markets alike. This growing patient population, combined with increasing awareness and insurance coverage for pharmaceutical obesity treatments, creates a favorable backdrop for multiple competitors.

Market size projections and dynamics:

• Projected market size: Nearly $100 billion by decade's end (2030s)
• Current dominance: Eli Lilly and Novo Nordisk control the majority of current market share through established GLP-1 therapies
• Competitive entry points: Dual and triple-agonist mechanisms, as well as alternative receptor targets, are attracting significant investment
• Patent landscape: Exclusivity periods and patent cliffs will reshape competitive positioning over the next 3-5 years

The competitive environment remains relatively open for well-capitalized companies with promising pipeline assets. Unlike some mature pharmaceutical markets where innovation has stalled, obesity therapeutics continues attracting substantial R&D investment and clinical trial activity. This dynamic environment creates opportunity for challenger companies that can successfully navigate late-stage development and regulatory approval processes.

Investor Implications: Why 2026 Could Be a Turning Point

Investors monitoring the obesity drug space should pay close attention to upcoming clinical trial readouts, as these events will likely serve as stock price catalysts for both Viking Therapeutics and AbbVie. Several factors support the bullish thesis:

Catalysts anticipated through 2026:

• Phase 3 trial completion and data releases for VK-2735 could demonstrate efficacy and safety advantages
• Further phase development progression for ABBV-295 with potential advancement toward later-stage trials
• Regulatory interactions and potential acceleration pathways (Fast Track designation, Breakthrough Therapy designation) that could expedite approval timelines
• Market expansion metrics showing continued patient demand and insurance coverage expansion

Successful trial outcomes could justify significant valuation expansion for these companies. The obesity drug market's growth trajectory is largely independent of broader economic cycles, representing a secular healthcare trend driven by disease prevalence and unmet medical needs. This defensive quality appeals to institutional investors seeking exposure to durable, growth-oriented healthcare themes.

For AbbVie specifically, obesity represents a potential new growth engine alongside its existing portfolio of immunology and specialty care products. For Viking Therapeutics, success with VK-2735 would validate the company's core therapeutic approach and potentially position it for acquisition interest from larger pharmaceutical companies seeking to expand obesity treatment portfolios.

However, investors should note that clinical development remains inherently uncertain. Trial results can disappoint, regulatory pathways may face unexpected obstacles, and competitive pressures could intensify if additional companies advance similar mechanisms simultaneously. Valuation multiples in the obesity drug space have expanded considerably, incorporating significant expectations about future growth.

Looking Ahead: A Market with Room for Multiple Winners

The projected $100 billion obesity drug market by decade's end is sufficiently large to accommodate multiple successful competitors operating distinct therapeutic mechanisms and market segments. Unlike markets where winner-take-most dynamics dominate, obesity treatment appears positioned for a more competitive landscape where patient heterogeneity, efficacy/safety profiles, and convenience factors allow multiple companies to achieve substantial commercial success.

The 2024-2026 period will prove decisive for both Viking Therapeutics and AbbVie. Clinical trial readouts, regulatory interactions, and market reception of new competitors will establish the competitive positioning that shapes the obesity treatment landscape for years to come. For investors with appropriate risk tolerance, monitoring these companies' clinical progress and maintaining awareness of trial timelines and results could provide meaningful opportunities as the obesity drug market continues its dramatic expansion.